孟鲁司特联合布地奈德治疗支气管哮喘患儿的临床观察

发布时间：2018-12-16 21:39

【摘要】：目的对儿童支气管患者使用孟鲁司特钠联合布地奈德进行治疗的效果以及安全性进行分析探讨。方法选择2016年1月至2017年6月收治的70例支气管哮喘患儿,随机分为观察组和对照组,每组各35例,其中对照组患儿给予常规的对症治疗,在此治疗方法的基础上,观察组患儿加用孟鲁司特钠以及布地奈德进行治疗,对两组患儿的用药治疗效果以及不良反应发生情况进行对比。结果观察组患儿和对照组患儿的临床治疗效果在有效以上的例数分别为33例(94.29%)和27例(77.14%),组间差异显著,存在统计学意义(P0.05);在咳嗽、喘息、哮鸣音等临床症状的消失时间方面,观察组患儿用时更短,与对照组之间的差异显著(P0.05);两组患儿均未发生明显的药物不良反应(P0.05),说明两种用药方案均具有较高的安全性。结论在儿童支气管哮喘的治疗中应用孟鲁司特钠以及布地奈德进行联合治疗,可使患儿的临床症状得到显著改善,在提高临床疗效的同时,可以保证患儿的用药安全,因此具有较高的临床应用价值。
[Abstract]:Objective to evaluate the efficacy and safety of montelukast sodium combined with budesonide in children with bronchi. Methods from January 2016 to June 2017, 70 children with bronchial asthma were randomly divided into observation group (n = 35) and control group (n = 35). Patients in the observation group were treated with montelukast sodium and budesonide. Results there were 33 cases (94.29%) and 27 cases (77.14%) in the observation group and the control group. The difference between the two groups was significant (P0.05). In the cough, asthma, wheezing and other clinical symptoms disappeared time, the observation group children with shorter time, and the control group between the significant difference (P0.05); No significant adverse drug reactions occurred in both groups (P0.05), indicating that the two drug regimens had higher safety. Conclusion the combined treatment of montelukast sodium and budesonide in the treatment of bronchial asthma in children can significantly improve the clinical symptoms of children and ensure the safety of drug use in children with bronchial asthma. Therefore, it has high clinical application value.
【作者单位】：内蒙古赤峰市敖汉旗医院;
【分类号】：R725.6

【相似文献】